INS and cancer: During a 5.4-year follow-up period, cancer-related mortality was 4.9% among SU users, 5.8% among insulin users, and 3.5% among metformin users, suggesting that metformin may offer protective effects against cancer, while insulin-promoting therapies may elevate oncogenic risk.